300 North Capital’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

300 North Capital’s Portfolio ARIA Stock Details ARIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-39,950	Closed	-$735K	–	123
2013 Q3	$735K	Hold	39,950	–	–	0.17%	102
2013 Q2	$699K	Buy	+39,950	New	+$708K	0.27%	89

Other funds holding ARIA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

300 North Capital's ARIA Position: Q4 2013 in Review

300 North Capital sold out of Ariad Pharmaceuticals Inc (ARIA) in Q4 2013, closing a stake of 39,950 shares — an estimated $735K sold.

300 North Capital first reported a position in ARIA in Q2 2013 and held it in 2 quarters. The position peaked at $735K in Q3 2013. 166 funds tracked by Wall St. Rank hold ARIA as of Q4 2013.

300 North Capital reported no remaining Ariad Pharmaceuticals Inc position as of Q4 2013 after selling out during the quarter.
300 North Capital sold 39,950 Ariad Pharmaceuticals Inc shares in Q4 2013, an estimated $735K.
300 North Capital first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 2 quarters.
300 North Capital's Ariad Pharmaceuticals Inc position peaked at $735K in Q3 2013.
166 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q4 2013.

Based on 300 North Capital's 13F filing for Q4 2013, filed 14 Feb 2014.